ARENA, FLAVIA
ARENA, FLAVIA
DIPARTIMENTO DI SCIENZE CLINICO-CHIRURGICHE, DIAGNOSTICHE E PEDIATRICHE
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
2021-01-01 Lasagna, A; Agustoni, F; Percivalle, E; Borgetto, S; Paulet, A; Comolli, G; Sarasini, A; Bergami, F; Sammartino, J C; Ferrari, A; Zavaglio, F; Arena, F; Lilleri, D; Secondino, S; Falzoni, M; Schiavo, R; Klersy, C; Lo Cascio, G; Cavanna, L; Baldanti, F; Pedrazzoli, P; Cassaniti, I
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
2022-01-01 Lasagna, A; Lilleri, D; Agustoni, F; Percivalle, E; Borgetto, S; Alessio, N; Comolli, G; Sarasini, A; Bergami, F; Sammartino, J C; Ferrari, A; Zavaglio, F; Arena, F; Secondino, S; Falzoni, M; Schiavo, R; Lo Cascio, G; Cavanna, L; Baldanti, F; Pedrazzoli, P; Cassaniti, I
Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers
2022-01-01 Bergami, F.; Arena, F.; Sammartino, J. C.; Ferrari, A.; Zavaglio, F.; Zelini, P.; Paolucci, S.; Comolli, G.; Percivalle, E.; Lilleri, D.; Cassaniti, I.; Baldanti, F.
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients
2023-01-01 Zavaglio, F.; Vitello, D.; Bergami, F.; Arena, F.; Borsani, O.; Colombo, A. A.; Caldera, D.; Lilleri, D.; Cassaniti, I.; Bernasconi, P.; Baldanti, F.
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
2022-01-01 Lasagna, A.; Bergami, F.; Lilleri, D.; Percivalle, E.; Quaccini, M.; Comolli, G.; Sarasini, A.; Sammartino, J. C.; Ferrari, A.; Arena, F.; Cicognini, D.; Schiavo, R.; Lo Cascio, G.; Baldanti, F.; Pedrazzoli, P.; Cassaniti, I.
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
2022-01-01 Lasagna, A.; Bergami, F.; Lilleri, D.; Percivalle, E.; Quaccini, M.; Serra, F.; Comolli, G.; Sarasini, A.; Sammartino, J. C.; Ferrari, A.; Arena, F.; Secondino, S.; Cicognini, D.; Schiavo, R.; Lo Cascio, G.; Cavanna, L.; Baldanti, F.; Pedrazzoli, P.; Cassaniti, I.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study | 1-gen-2021 | Lasagna, A; Agustoni, F; Percivalle, E; Borgetto, S; Paulet, A; Comolli, G; Sarasini, A; Bergami, F; Sammartino, J C; Ferrari, A; Zavaglio, F; Arena, F; Lilleri, D; Secondino, S; Falzoni, M; Schiavo, R; Klersy, C; Lo Cascio, G; Cavanna, L; Baldanti, F; Pedrazzoli, P; Cassaniti, I | |
| Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up | 1-gen-2022 | Lasagna, A; Lilleri, D; Agustoni, F; Percivalle, E; Borgetto, S; Alessio, N; Comolli, G; Sarasini, A; Bergami, F; Sammartino, J C; Ferrari, A; Zavaglio, F; Arena, F; Secondino, S; Falzoni, M; Schiavo, R; Lo Cascio, G; Cavanna, L; Baldanti, F; Pedrazzoli, P; Cassaniti, I | |
| Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers | 1-gen-2022 | Bergami, F.; Arena, F.; Sammartino, J. C.; Ferrari, A.; Zavaglio, F.; Zelini, P.; Paolucci, S.; Comolli, G.; Percivalle, E.; Lilleri, D.; Cassaniti, I.; Baldanti, F. | |
| Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients | 1-gen-2023 | Zavaglio, F.; Vitello, D.; Bergami, F.; Arena, F.; Borsani, O.; Colombo, A. A.; Caldera, D.; Lilleri, D.; Cassaniti, I.; Bernasconi, P.; Baldanti, F. | |
| Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment | 1-gen-2022 | Lasagna, A.; Bergami, F.; Lilleri, D.; Percivalle, E.; Quaccini, M.; Comolli, G.; Sarasini, A.; Sammartino, J. C.; Ferrari, A.; Arena, F.; Cicognini, D.; Schiavo, R.; Lo Cascio, G.; Baldanti, F.; Pedrazzoli, P.; Cassaniti, I. | |
| Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern | 1-gen-2022 | Lasagna, A.; Bergami, F.; Lilleri, D.; Percivalle, E.; Quaccini, M.; Serra, F.; Comolli, G.; Sarasini, A.; Sammartino, J. C.; Ferrari, A.; Arena, F.; Secondino, S.; Cicognini, D.; Schiavo, R.; Lo Cascio, G.; Cavanna, L.; Baldanti, F.; Pedrazzoli, P.; Cassaniti, I. |